Recombinant Human Coiled-coil domain-containing protein 6 (CCDC6)

中文名稱：

Recombinant Human Coiled-coil domain-containing protein 6(CCDC6)
貨號(hào)：

CSB-YP623068HU
說(shuō)明書：

MSDS Datasheet
規(guī)格：
來(lái)源：

Yeast
其他：

中文名稱：

Recombinant Human Coiled-coil domain-containing protein 6(CCDC6)
貨號(hào)：

CSB-EP623068HU
說(shuō)明書：

MSDS Datasheet
規(guī)格：
來(lái)源：

E.coli
其他：

中文名稱：

Recombinant Human Coiled-coil domain-containing protein 6(CCDC6)
貨號(hào)：

CSB-EP623068HU-B
說(shuō)明書：

MSDS Datasheet
規(guī)格：
來(lái)源：

E.coli
共軛：

Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
其他：

中文名稱：

Recombinant Human Coiled-coil domain-containing protein 6(CCDC6)
貨號(hào)：

CSB-BP623068HU
說(shuō)明書：

MSDS Datasheet
規(guī)格：
來(lái)源：

Baculovirus
其他：

中文名稱：

Recombinant Human Coiled-coil domain-containing protein 6(CCDC6)
貨號(hào)：

CSB-MP623068HU
說(shuō)明書：

MSDS Datasheet
規(guī)格：
來(lái)源：

Mammalian cell
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

>85% (SDS-PAGE)
基因名：

CCDC6
Uniprot No.：

Q16204
別名：

CCDC 6; CCDC6; CCDC6_HUMAN; Coiled coil domain containing 6; Coiled coil domain containing protein 6; Coiled-coil domain-containing protein 6; D10S170; FLJ32286; H4; Papillary thyroid carcinoma encoded protein; Papillary thyroid carcinoma-encoded protein; Protein H4; PTC; TPC; TST 1; TST1
種屬：

Homo sapiens (Human)
蛋白長(zhǎng)度：

Full Length of Mature Protein
表達(dá)區(qū)域：

2-474
氨基酸序列

ADSASESDT DGAGGNSSSS AAMQSSCSST SGGGGGGGGG GGGGKSGGIV ISPFRLEELT NRLASLQQEN KVLKIELETY KLKCKALQEE NRDLRKASVT IQARAEQEEE FISNTLFKKI QALQKEKETL AVNYEKEEEF LTNELSRKLM QLQHEKAELE QHLEQEQEFQ VNKLMKKIKK LENDTISKQL TLEQLRREKI DLENTLEQEQ EALVNRLWKR MDKLEAEKRI LQEKLDQPVS APPSPRDISM EIDSPENMMR HIRFLKNEVE RLKKQLRAAQ LQHSEKMAQY LEEERHMREE NLRLQRKLQR EMERREALCR QLSESESSLE MDDERYFNEM SAQGLRPRTV SSPIPYTPSP SSSRPISPGL SYASHTVGFT PPTSLTRAGM SYYNSPGLHV QHMGTSHGIT RPSPRRSNSP DKFKRPTPPP SPNTQTPVQP PPPPPPPPMQ PTVPSAATSQ PTPSQHSAHP SSQP
蛋白標(biāo)簽：

Tag?type?will?be?determined?during?the?manufacturing?process.

The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
產(chǎn)品提供形式：

Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
復(fù)溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲(chǔ)存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet ：

Please contact us to get it.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

基因功能參考文獻(xiàn)：
1. FGFR inhibitors, particularly BGJ398, are therapeutic options for cholangiocarcinoma patients harboring FGFR2-CCDC6 fusions. PMID: 27216979
2. Our findings nevertheless suggest that CCDC6-RET fusions identified by multiplex testing are potential targets for nintedanib therapy. PMID: 26787234
3. we propose that the amount of CCDC6 protein in primary tumors, as reported in lung, may depend on the impairment of the CCDC6 turnover due to altered protein-protein interaction and post-translational modifications PMID: 25885523
4. Results show that RNA-binding protein EWS binds and regulates CCDC6 expression at RNA and protein levels. PMID: 25751255
5. CCDC6 levels provide valuable insight for OS. PMID: 25302833
6. the loss of CCDC6 could aid the spermatogonial cells to be part of a pro-survival pathway that helps to evade the toxic effects of endogenous oxidants and contributes to testicular neoplastic growth. PMID: 24059746
7. Expression of the CCDC6-RET fusion gene in LC-2/ad cells was demonstrated by the mRNA and protein levels, and the genomic break-point was confirmed by genomic DNA sequencing. PMID: 23578175
8. CCDC6 is associated with cAMP signaling by fine regulating CREB1 transcriptional activity in normal and transformed thyroid cells. PMID: 23145146
9. CCDC6-RET fusion is associated with lung adenocarcinoma. PMID: 23154560
10. It was shown that FBXW7 interacts with and targets CCDC6 for ubiquitin-mediated proteasomal degradation. FBXW7-mediated CCDC6 degradation was impaired in response to DNA damage. PMID: 23108047
11. Following genotoxic stress, loss or inactivation of CCDC6 in cancers that carry the CCDC6 fusion, accelerates the dephosphorylation of pH2AX S139, resulting in defective G2 arrest and premature mitotic entry. PMID: 22655027
12. CCDC6 plays a key role in cell cycle control. PMID: 22363533
13. we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas PMID: 22327623
14. down-regulation of 14-3-3sigma in the absence of CCDC6 demonstrated their direct association and supports the notion that CCDC6 contributes to cancer development, possibly through malignant pathways involving 14-3-3sigma PMID: 22399611
15. repression of CREB1 activity by CCDC6 has a critical function in the development of human thyroid papillary carcinomas carrying RET/PTC1 activation. PMID: 20498639
16. H4(D10S170) is involved in the cellular response to ataxia telangectasia mutated (ATM) kinase; impairment of H4(D10S170) gene function might have a role in thyroid carcinogenesis. PMID: 17420723
17. frequency of the occurrence of BRAF mutation and/or RET/PTC in H4-PTEN positive tumors was extremely high (75%) in papillary thyroid carcinoma PMID: 18226854
18. PTC1 and PTC3 are highly oncogenic proteins when overexpressed, but result in indolent disease compared with RET-related MTCs due to their relatively low expression from the NCOA4 and CCDC6 promoters in vivo. PMID: 19487296
顯示更多

收起更多
相關(guān)疾?。?/div>
A chromosomal aberration involving CCDC6 is found in papillary thyroid carcinomas (PTCs). Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene.
亞細(xì)胞定位：

Cytoplasm. Cytoplasm, cytoskeleton. Note=May be a cytoskeletal protein.
組織特異性：

Ubiquitously expressed.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 18782

OMIM: 601985

KEGG: hsa:8030

STRING: 9606.ENSP00000263102

UniGene: Hs.591360